nach oben

Die Pathologie

Erschienen in:

11.10.2023 | Tyrosinkinaseinhibitoren | Schwerpunkt: Kindliche Tumoren

Rezeptor-Tyrosinkinase-Fusionen in spindelzelligen Tumoren des Kindesalters

verfasst von: Dr. Christiane Brenner, Christine Sanders, Christian Vokuhl

Erschienen in: Die Pathologie | Ausgabe 6/2023

Einloggen, um Zugang zu erhalten

Zusammenfassung

Spindelzellige Tumoren des Kindesalters sind selten und bereiten diagnostisch häufig Schwierigkeiten, da sie ein morphologisch ähnliches Bild und ein uncharakteristisches immunhistochemisches Profil aufweisen. Durch die immer besser werdende genetische Charakterisierung dieser Läsionen wurden neue Subgruppen identifiziert, die zum Teil in die neueste WHO-Klassifizierung miteinbezogen wurden. Bei diesen Tumoren spielen vor allem die sog. Rezeptor-Tyrosinkinase-Fusionen eine Rolle. Hierbei handelt es sich um Fusionen mit Beteiligung der Gene NTRK1-3, ALK, RET und ROS1. Der Nachweis einer Fusion ist von diagnostischer Bedeutung und kann auch eine Option für zielgerichtete Therapien bieten. Insgesamt handelt es sich bei kindlichen spindelzelligen Tumoren mit Rezeptor-Tyrosinkinase-Fusionen überwiegend um low-grade Tumoren, welche häufig in die Gruppe der intermediär-malignen Tumoren eingeteilt werden.

Erdmann F et al (2021) Impact of the COVID-19 pandemic on incidence, time of diagnosis and delivery of healthcare among paediatric oncology patients in Germany in 2020: Evidence from the German Childhood Cancer Registry and a qualitative survey. Lancet Reg Health 9:100188. https://doi.org/10.1016/j.lanepe.2021.100188CrossRef

Scheidt S et al (2019) Soft tissue sarcoma—a current review of the diagnostic and treatment strategies. Z Orthop Unfall 157:644–653. https://doi.org/10.1055/a-0820-6366CrossRefPubMed

Mitelman F, Johansson B, Mertens F (2007) The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer 7:233–245. https://doi.org/10.1038/nrc2091CrossRefPubMed

Lawrence B et al (2000) TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am J Pathol 157:377–384. https://doi.org/10.1016/S0002-9440(10)64550-6CrossRefPubMedPubMedCentral

Cocco E, Scaltriti M, Drilon A (2018) NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 15:731–747. https://doi.org/10.1038/s41571-018-0113-0CrossRefPubMedPubMedCentral

Filbin M, Monje M (2019) Developmental origins and emerging therapeutic opportunities for childhood cancer. Nat Med 25:367–376. https://doi.org/10.1038/s41591-019-0383-9CrossRefPubMedPubMedCentral

LaHaye S et al (2021) Discovery of clinically relevant fusions in pediatric cancer. BMC Genom 22:872. https://doi.org/10.1186/s12864-021-08094-zCrossRef

Villani A et al (2023) The clinical utility of integrative genomics in childhood cancer extends beyond targetable mutations. Nat Cancer 4:203–221. https://doi.org/10.1038/s43018-022-00474-yCrossRefPubMed

Lang SS et al (2022) Neurotrophic tyrosine receptor kinase fusion in pediatric central nervous system tumors. Cancer Genet 262–263:64–70. https://doi.org/10.1016/j.cancergen.2022.01.003CrossRefPubMed

10.

Bertrand T et al (2012) The crystal structures of TrkA and TrkB suggest key regions for achieving selective inhibition. J Mol Biol 423:439–453. https://doi.org/10.1016/j.jmb.2012.08.002CrossRefPubMed

11.

Hechtman JF (2021) NTRK insights: best practices for pathologists. Mod Pathol 35:298–305. https://doi.org/10.1038/s41379-021-00913-8CrossRefPubMedCentral

12.

Roosen M et al (2022) The oncogenic fusion landscape in paediatric CNS neoplasms. Acta Neuropathol 143:427–451. https://doi.org/10.1007/s00401-022-02405-8CrossRefPubMedPubMedCentral

13.

Solomon JP et al (2020) NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol 33:38–46. https://doi.org/10.1038/s41379-019-0324-7CrossRefPubMed

14.

Chetty R (2019) Neurotrophic tropomyosin or tyrosine receptor kinase (NTRK) genes. J Clin Pathol 72:187–190. https://doi.org/10.1136/jclinpath-2018-205672CrossRefPubMed

15.

Hung YP, Fletcher CDM, Hornick JL (2018) Evaluation of pan-TRK immunohistochemistry in infantile fibrosarcoma, lipofibromatosis-like neural tumour and histological mimics. Histopathology 73:634–644. https://doi.org/10.1111/his.13666CrossRefPubMed

16.

Bellantoni AJ, Wagner LM (2021) Pursuing precision: receptor tyrosine kinase inhibitors for treatment of pediatric solid tumors. Cancers 13:3531. https://doi.org/10.3390/cancers13143531CrossRefPubMedPubMedCentral

17.

Carton M et al (2023) Larotrectinib versus historical standard of care in patients with infantile fibrosarcoma: protocol of EPI-VITRAKVI. Future Oncol Prepr. https://doi.org/10.2217/fon-2023-0114CrossRef

18.

Kao Y et al (2020) Soft tissue tumors characterized by a wide spectrum of kinase fusions share a lipofibromatosis-like neural tumor pattern. Genes Chromosom Cancer 59:575–583. https://doi.org/10.1002/gcc.22877CrossRefPubMed

19.

Suurmeijer AJ et al (2019) The histologic spectrum of soft tissue spindle cell tumors with NTRK3 gene rearrangements. Genes Chromosomes Cancer 58:739–746. https://doi.org/10.1002/gcc.22767CrossRefPubMedPubMedCentral

20.

Kang J et al (2020) Clinicopathological findings of pediatric NTRK fusion mesenchymal tumors. Diagn Pathol 15:114. https://doi.org/10.1186/s13000-020-01031-wCrossRefPubMedPubMedCentral

21.

Pavlick D et al (2017) Identification of NTRK fusions in pediatric mesenchymal tumors. Pediatr Blood Cancer 64:8. https://doi.org/10.1002/pbc.26433CrossRef

22.

Chan JK et al (2001) Anaplastic lymphoma kinase expression in inflammatory pseudotumors. Am J Surg Pathol 25:761–768CrossRefPubMed

23.

O’Haire S et al (2023) Systematic review of NTRK 1/2/3 fusion prevalence pan-cancer and across solid tumours. Sci Rep 13:4116. https://doi.org/10.1038/s41598-023-31055-3CrossRefPubMedPubMedCentral

24.

Lovly CM et al (2014) Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. Cancer Discov 4:889–895. https://doi.org/10.1158/2159-8290.CD-14-0377CrossRefPubMedPubMedCentral

25.

Hornick JL et al (2015) Modern Pathology 5:732–739. https://doi.org/10.1038/modpathol.2014.165CrossRef

26.

Preobrazhenskaya EV et al (2020) Gene rearrangements in consecutive series of pediatric inflammatory myofibroblastic tumors. Pediatr Blood Cancer 67:e28220. https://doi.org/10.1002/pbc.28220CrossRefPubMed

27.

Siemion K et al (2022) What do we know about inflammatory myofibroblastic tumors? – A systematic review. Advances in Medical Sciences 67:129–138. https://doi.org/10.1016/j.advms.2022.02.002CrossRefPubMed

28.

Davis JL et al (2019) Expanding the spectrum of paediatric NTRK-rearranged mesenchymal tumors. Am J Surg Pathol 43:435–445. https://doi.org/10.1097/PAS.0000000000001203CrossRefPubMed

29.

Davis JL et al (2020) Recurrent RET gene fusions in paediatric spindle mesenchymal neoplasms. Histopathology 76:1032–1041CrossRefPubMed

30.

Antonescu CR et al (2015) Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement. Am J Surg Pathol 39:957–967. https://doi.org/10.1097/PAS.0000000000000404CrossRefPubMedPubMedCentral

31.

Antonescu CR (2020) Emerging soft tissue tumors with kinase fusions: An overview of the recent literature with an emphasis on diagnostic criteria. Genes Chromosomes Cancer 59:437–444. https://doi.org/10.1002/gcc.22846CrossRefPubMedPubMedCentral

32.

Flucke U et al (2017) TFG-MET fusion in an infantile spindle cell sarcoma with neural features. Genes. Chromosomes & Cancer 56:663–667. https://doi.org/10.1002/gcc.22470CrossRef

33.

Ulschmid CM et al (2023) Lipofibromatosis-like neural tumors: Report of a case and review of 73 reported cases. Pediatric Dermatology 40:664–668. https://doi.org/10.1111/pde.15218CrossRefPubMed

34.

Kube S et al (2018) Inflammatory myofibroblastic tumors—A retrospective analysis of the Cooperative Weichteilsarkom Studiengruppe. Pediatr Blood Cancer 65:e27012. https://doi.org/10.1002/pbc.27012CrossRefPubMed

35.

Hernández L et al (1999) TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. Blood 94:3265–3268. https://doi.org/10.1200/JCO.2012.44.5353CrossRefPubMed

36.

Morris SW et al (1997) ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin’s lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene 14:2175–2188. https://doi.org/10.1038/sj.onc.1201062CrossRefPubMed

37.

Hallberg B, Palmer RH (2016) The role of the ALK receptor in cancer biology. Ann Oncol 27:iii4–iii15. https://doi.org/10.1016/j.biopha.2022.114162CrossRefPubMed

38.

Cajaiba MM et al (2016) ALK-rearranged renal cell carcinomas in children. Genes Chromosomes Cancer 55:442–451. https://doi.org/10.1002/gcc.22346CrossRefPubMed

39.

Coffin CM, Hornick JL, Fletcher CDM (2007) Inflammatory myofibroblastic tumor comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am J Surg Pathol 31:509–520. https://doi.org/10.1097/01.pas.0000213393.57322.c7CrossRefPubMed

40.

Mariño-Enriquez A et al (2011) Epithelioid inflammatory myofibroblastic sarcoma: an aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or Perinuclear ALK. Am J Surg Pathol 35:135–144. https://doi.org/10.1097/PAS.0b013e318200cfd5CrossRefPubMed

41.

Cessna MH et al (2002) Expression of ALK1 and p80 in inflammatory myofibroblastic tumor and its mesenchymal mimics: a study of 135 cases. Mod Pathol 15:931–938. https://doi.org/10.1097/01.MP.0000026615.04130.1FCrossRefPubMed

42.

Chen S, Lee J (2008) An inflammatory myofibroblastic tumor in liver with ALK and RANBP2 gene rearrangement: combination of distinct morphologic, immunohistochemical, and genetic features. Hum Pathol 39:1854–1858. https://doi.org/10.1016/j.humpath.2008.04.016CrossRefPubMed

43.

Gros L, Dei Tos AP, Jones RL, Digklia A (2022) Inflammatory myofibroblastic tumour: state of the art. Cancers 14:3662. https://doi.org/10.3390/cancers14153662CrossRefPubMedPubMedCentral

44.

Brivio E, Zwaan CM (2019) ALK inhibition in two emblematic cases of pediatric inflammatory myofibroblastic tumor: efficacy and side effects. Pediatr Blood Cancer 66:e27645. https://doi.org/10.1002/pbc.27645CrossRefPubMed

45.

Birchmeier C (1986) Characterization of an Activated Human ros Gene. Mol Cell Biol 6:3109–3116. https://doi.org/10.1128/mcb.6.9.3109-3116.1986CrossRefPubMedPubMedCentral

46.

Gainor JF, Shaw AT (2013) Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist 18:865–875. https://doi.org/10.1634/theoncologist.2013-0095CrossRefPubMedPubMedCentral

47.

Chen L et al (2021) Fibroblast growth factor receptor fusions in cancer: opportunities and challenges. J Exp Clin Cancer Res 40:345. https://doi.org/10.1186/s13046-021-02156CrossRefPubMedPubMedCentral

48.

Cheek EH et al (2020) Uterine inflammatory myofibroblastic tumors in pregnant women with and without involvement of the placenta: a study of 6 cases with identification of a novel TIMP3-RET fusion. Hum Pathol 97:29–39. https://doi.org/10.1016/j.humpath.2019.12.006CrossRefPubMed

49.

Vokuhl C (2019) Kindliche Tumoren mit Spindelzellmorphologie. Pathologe 40:381–392. https://doi.org/10.1007/s00292-019-0602-7CrossRefPubMed

50.

Wardelmann E, Hartmann W (2021) Neues in der aktuellen WHO-Klassifikation (2020) für Weichgewebssarkome. Pathologe 42:281–293. https://doi.org/10.1007/s00292-021-00935-8CrossRefPubMed

51.

Antonescu CR et al (2019) Spindle cell tumors with RET gene fusions exhibit a morphologic spectrum akin to tumors with NTRK gene fusions. Am J Surg Pathol 43:1384–1391. https://doi.org/10.1097/PAS.0000000000001297CrossRefPubMedPubMedCentral

52.

Heydt C et al (2019) Comparison of in situ and extraction-based methods for the detection of ROS1 rearrangements in solid tumors. J Mol Diagn 21:971–984. https://doi.org/10.1016/j.jmoldx.2019.06.006CrossRefPubMed

53.

Stenzinger A et al (2021) Diagnostik und Therapie von Tumoren mit NTRK-Genfusionen. Pathologe 42:103–115. https://doi.org/10.1007/s00292-020-00864-yCrossRefPubMed

54.

Sorokin M et al (2022) Clinically relevant fusion oncogenes: detection and practical implications. Ther Adv Med Oncol 14:1–34. https://doi.org/10.1177/17588359221144108CrossRef

55.

Gatalica Z et al (2019) Molecular characterization of cancers with NTRK gene fusions. Mod Pathol 32:147–153. https://doi.org/10.1038/s41379-018-0118-3CrossRefPubMed

56.

Hechtman JF (2017) Pan-Trk Immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions. Am J Surg Pathol 41:1547–1551. https://doi.org/10.1097/PAS.0000000000000911CrossRefPubMedPubMedCentral

57.

Rudzinski ER et al (2018) Pan-Trk Immunohistochemistry identifies NTRK rearrangements in pediatric mesenchymal tumors. Am J Surg Pathol 42:927–935. https://doi.org/10.1097/PAS.0000000000001062CrossRefPubMed

58.

Prescott JD, Zeiger MA (2015) The RET oncogene in papillary thyroid carcinoma. Cancer 121:2137–2146. https://doi.org/10.1002/cncr.29044CrossRefPubMed

59.

Belli C et al (2021) ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research. Ann Oncol 32:337–350. https://doi.org/10.1016/j.annonc.2020.11.021CrossRefPubMed

60.

Dacic S et al (2016) ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma. Oncotarget 13:82943–82952. https://doi.org/10.18632/oncotarget.12705CrossRef

61.

Pekar-Zlotin M et al (2015) Fluorescence in situ hybridization, Immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer. The Oncol 20:316–322. https://doi.org/10.1634/theoncologist.2014-0389CrossRef

62.

Wynes MW (2014) An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. J Thorac Oncol 9:631–638. https://doi.org/10.1097/JTO.0000000000000115CrossRefPubMedPubMedCentral

63.

Ambati SR et al (2018) Entrectinib in two pediatric patients with inflammatory myofibroblastic tumors harboring ROS1 or ALK gene fusions. JCO Precis Oncol. https://doi.org/10.1200/PO.18.00095CrossRefPubMedPubMedCentral

64.

Rangaraju S et al (2017) TRTH-10. Pediatric Phase 1/1B Study of Entrectinib in patients with primary brain tumors, neuroblastoma and NTRK, ROS1, or ALK Fusions. Neuro Oncol 19:iv53. https://doi.org/10.1093/neuonc/nox083.222CrossRefPubMedCentral

65.

Mossé YP et al (2017) Targeting ALK with crizotinib in pediatric anaplastic large cell Lymphoma and inflammatory myofibroblastic tumor: a children’s oncology group study. JCO 35:3215–3221. https://doi.org/10.1200/JCO.2017.73.4830CrossRef

66.

Theilen T (2018) Crizotinib in ALK⁺ inflammatory myofibroblastic tumors-Current experience and future perspectives. Pediatr Blood Cancer 65:e26920. https://doi.org/10.1002/pbc.26920CrossRef

67.

D’Angelo A et al (2020) Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies. Cancers 12:3293. https://doi.org/10.3390/cancers12113293CrossRefPubMedPubMedCentral

68.

Keino D et al (2020) Pilot study of the combination of sorafenib and fractionated irinotecan in pediatric relapse/refractory hepatic cancer (FINEX pilot study). Pediatr Blood Cancer 67:e28655. https://doi.org/10.1002/pbc.28655CrossRefPubMed

69.

Ortiz MV et al (2020) Activity of the Highly Specific RET Inhibitor Selpercatinib. LOXO, Bd. 292., S 341–347 https://doi.org/10.1200/PO.19.00401CrossRef

70.

https://ema.europa.eu/en/documents/product-information/retsevmo-epar-product-information_de.pdf

71.

Laetsch TW et al (2018) The Lancet Oncology 1(8):30119–30110. https://doi.org/10.1016/S1470-2045CrossRef

72.

www.dgho.de. Zugegriffen: 2. Aug. 2023

Titel: Rezeptor-Tyrosinkinase-Fusionen in spindelzelligen Tumoren des Kindesalters
verfasst von: Dr. Christiane Brenner
Christine Sanders
Christian Vokuhl
Publikationsdatum: 11.10.2023
Verlag: Springer Medizin
Schlagwörter: Tyrosinkinaseinhibitoren
Tyrosinkinaseinhibitoren
FISH-Analysen
Zielgerichtete Therapie
Lymphome
Crizotinib
Anaplastisches großzelliges Lymphom
Anaplastisches großzelliges Lymphom
Pädiatrische Tumoren
Erschienen in: Die Pathologie / Ausgabe 6/2023
Print ISSN: 2731-7188
Elektronische ISSN: 2731-7196
DOI: https://doi.org/10.1007/s00292-023-01228-y

Passend zum Thema

AGO-Leitlinie 2024: Update zu CDK4 & 6 Inhibitoren

Die Kommission Mamma der Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) hat am 02. März 2024 ihre aktualisierten Empfehlungen präsentiert.[1,2] Welchen Stellenwert CDK4 & 6 Inhibitoren in der Therapie des Hormonrezeptor-positiven (HR+), HER2-negativen (HER2-) Mammakarzinoms haben, erfahren Sie hier im Update.

Finale OS-Analyse der MONARCH-3-Studie vorgestellt

In der MONARCH-3-Studie erhielten Patientinnen mit fortgeschrittenem HR+, HER2- Brustkrebs Abemaciclib [1,a] in Kombination mit nicht-steroidalem Aromatasehemmer (nsAI). Die finalen Daten bestätigen den in früheren Analysen beobachteten Unterschied zugunsten der Kombinationstherapie. [2] Details dazu vom SABCS 2023.

Die Bedeutung der CDK4 & 6 Inhibition beim HR+, HER2- Mammakarzinom

Es erwarten Sie praxisrelevante Patientenfälle, kompakte Studiendarstellungen, informative Experteninterviews sowie weitere spannende Inhalte rund um das HR+, HER2- Mammakarzinom.

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2023

Grundlagen der Pathologie von Keimzelltumoren des Hodens

Pleomorphes Adenom der Peribronchialdrüsen

Kindliche Hirntumoren

Periphere neuroblastische Tumoren im Kindesalter

Die Verordnung (EU) 2017/746 (IVDR) in der Praxis: Umsetzung von Anhang I in der Pathologie

Molekulare Klassifikation des Endometriumkarzinoms – ein kurzer Überblick

Passend zum Thema

AGO-Leitlinie 2024: Update zu CDK4 & 6 Inhibitoren

Finale OS-Analyse der MONARCH-3-Studie vorgestellt

Die Bedeutung der CDK4 & 6 Inhibition beim HR+, HER2- Mammakarzinom